IP Library › Granted Patent US 12,544,413
Granted Patent B2
US 12,544,413 · App. 17/607,827 · Granted Feb 10, 2026

Composition with antibacterial and re-epithelializing action including probiotics

Inventor: Gino Santini (Ardea, IT)
Assignee: EOS2021 S.R.L.
A61K35/747A61F13/00063A61P17/02A61P31/04C12N1/20C12R2001/07C12R2001/23C12R2001/25C12R2001/46
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,544,413
App. No.
17/607,827
Granted
Feb 10, 2026
Kind
B2
Abstract

The present invention relates to the strain of Lactobacillus plantarum NCIMB 43029, the strain of Lactobacillus acidophilus NCIMB 43030, a composition with both antibacterial and re-epithelializing action which includes Lactobacillus plantarum and Lactobacillus acidophilus and optionally Streptococcus thermophilus and/or Bacillus amyloliquefaciens intended to be used as a medicament for the re-epithelialisation of lesions or wounds, a bandage comprising said composition and kits comprising such a composition.

Claims (36)

1 . A medicine or medicament comprising:

(a) a bacterial combination comprising:

(i) a Lactobacillus plantarum;

(ii) a Lactobacillus acidophilus strain;

(iii) a Streptococcus thermophilus strain; or combination thereof, and

(b) a Bacillus amyloliquefaciens comprising a 16S rRNA as encoded by SEQ ID NO: 10,

wherein the Lactobacillus plantarum comprises:

(1) a Lactobacillus plantarum strain with accession number NCIMB 43029, or

(2) a Lactobacillus plantarum strain comprising the hyper variable regions V1-V3 of a gene encoding for 16S rRNA of SEQ ID NO: 4, a groEL gene of SEQ ID NO: 5 and a pheS gene of SEQ ID NO: 6, and

wherein the Lactobacillus acidophilus strain comprises:

(1) a Lactobacillus acidophilus strain with accession number NCIMB 43030, or

(2) a Lactobacillus acidophilus strain comprising the hyper variable regions V1-V3 of a gene encoding for the 16S rRNA of SEQ ID NO: 1, a groEL gene of SEQ ID NO: 2 and a pheS gene of SEQ ID NO:3,

wherein the Streptococcus thermophilus strain comprises the hyper variable regions V1-V2 of a gene encoding for the 16S rRNA of SEQ ID NO: 7, a recA gene of SEQ ID NO: 8 and a secA gene of SEQ ID NO: 9.

2 . The medicine or medicament of claim 1 , formulated for oral or topical use, or formulated as a powder, a granule, a gingival tablet, a vaginal tablet, a capsule or a gel.

3 . The medicine or medicament of claim 1 , wherein:

(a) the percentage by weight of the Lactobacillus plantarum in the medicine or medicament is in the range of 1% to 40% by weight on the basis of the total weight of the medicine or medicament;

(b) the percentage by weight of the Lactobacillus acidophilus in the medicine or medicament is in the range of 1% to 40% by weight on the basis of the total weight of the medicine or medicament;

(c) the percentage by weight of the Streptococcus thermophilus in the medicine or medicament is in the range of 0.5% to 20% by weight on the basis of the total weight of the medicine or medicament;

(d) the percentage by weight of the Bacillus amyloliquefaciens in the medicine or medicament is in the range of 0.1% to 10% by weight on the basis of the total weight of the medicine or medicament;

(e) the medicine or medicament comprises from between about 10% to 90% by weight of Lactobacillus plantarum , and from between about 90% to 10% by weight of Lactobacillus acidophilus on the basis of the total weight of the medicine or medicament;

(f) the medicine or medicament comprises from between about 20% to 80% by weight of Lactobacillus plantarum , from between about 40% to 10% by weight of Lactobacillus acidophilus , and from between about 40% to 10% by weight of Streptococcus thermophilus on the basis of the total weight of the medicine or medicament;

(g) the medicine or medicament comprises from between about 10% to 80% by weight of Lactobacillus plantarum , from between about 40% to 10% by weight of Lactobacillus acidophilus , from between about 40% to 9% by weight of Streptococcus thermophilus , and from between about 10% to 1% by weight of Bacillus amyloliquefaciens on the basis of the total weight of the medicine or medicament;

(h) the Lactobacillus plantarum, Lactobacillus acidophilus, Streptococcus thermophilus and Bacillus amyloliquefaciens are live bacteria; or

(i) the Lactobacillus plantarum, Lactobacillus acidophilus, Streptococcus thermophilus and Bacillus amyloliquefaciens are non-viable.

4 . The medicine or medicament of claim 1 , formulated for topical administration.

5 . The medicine or medicament of claim 1 , formulated as a powder or granules for topical administration.

6 . The medicine or medicament of claim 1 , incorporated in a bandage for topical administration of the medicine or medicament.

7 . The medicine or medicament of claim 1 , formulated with a pharmaceutically acceptable excipient.

8 . The medicine or medicament of claim 7 , wherein the pharmaceutically acceptable excipient comprises algae, bee pollen, honey, ventilated clay or zeolite.

9 . The medicine or medicament of claim 1 , where the bacterial combination of step (a) comprises:

(i) a Lactobacillus plantarum;

(ii) a Lactobacillus acidophilus strain; and

(iii) a Streptococcus thermophilus strain.

10 . The medicine or medicament of claim 1 , where the bacterial combination of step (a) comprises:

(i) a Lactobacillus plantarum ; and

(ii) a Lactobacillus acidophilus strain.

Assignments (3)
CHANGE OF NAME Recorded Oct 13, 2025
From: MENDES S.R.L.
To: EOS2021 S.R.L.
Reel/Frame 073084/0566 →
CHANGE OF NAME Recorded Nov 27, 2024
From: MENDES S.R.L
To: EOS2021 S.R.L
Reel/Frame 069458/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2022
From: SANTINI, GINO
To: MENDES S.R.L.
Reel/Frame 059490/0611 →
Priority Claims (1)
IT 102019000009951 · Jun 24, 2019 · national
Continuity (1)
Related Publication 20230310522A1 · Oct 5, 2023
References Cited (33)
US 9308227B2 · Lang · 2016 [cited by examiner]
CN 105343133A · 2016 [cited by applicant]
CN 106922816A · 2017 [cited by applicant]
CN 107106480A · 2017 [cited by applicant]
CN 107208107A · 2017 [cited by applicant]
CN 109497517A · 2019 [cited by applicant]
KR 20130002534A · 2013 [cited by applicant]
KR 101919938B1 · 2019 [cited by examiner]
KR 20190060556A · 2019 [cited by applicant]
WO WO016124266A1 · 2008 [cited by applicant]
WO WO2011146715A1 · 2011 [cited by applicant]
Watts et al. 16S rRNA gene sequencing on a benchtop sequencer: accuracy for identification of clinically important bacteria. J Appl Microbiol. 2017;123(6):1584-1596. [cited by examiner]
Park et al. Lactobacillus plantarum HAC01 regulates gut microbiota and adipose tissue accumulation in a diet-induced obesity murine model. Appl Microbiol Biotechnol. 2017; 101:1605-1614. [cited by examiner]
Wang et al. Bacillus amyloliquefaciens SC06 alleviates the oxidative stress of IPEC-1 via modulating Nrf2/Keap1 signaling pathway and decreasing ROS production. Appl Microbiol Biotechnol. 2017; 101:3015-3026. [cited by examiner]
Marseglia et al. Oxidative Stress in Obesity: A Critical Component in Human Diseases. Int. J. Mol. Sci. 2015;16:378-400. [cited by examiner]
SEQ ID No. 4, GenBank Blast, cited in Park et al. Lactobacillus plantarum HAC01 regulates gut microbiota and adipose tissue accumulation in a diet-induced obesity murine model. Appl Microbiol Biotechnol. 2017; 101:1605-… [cited by examiner]
SEQ ID No. 5, GenBank Blast, cited in Park et al. Lactobacillus plantarum HAC01 regulates gut microbiota and adipose tissue accumulation in a diet-induced obesity murine model. Appl Microbiol Biotechnol. 2017; 101:1605-… [cited by examiner]
SEQ ID No. 6, GenBank Blast, cited in Park et al. Lactobacillus plantarum HAC01 regulates gut microbiota and adipose tissue accumulation in a diet-induced obesity murine model. Appl Microbiol Biotechnol. 2017;101:1605-1… [cited by examiner]
Salaran et al. Topical Application of Lactobacillus Plantarum on Burn Wound Healing in Diabetic Rats. IJVS. 2019;14(1):60-72. [cited by examiner]
Komosinska-Vassev et al. Bee Pollen: Chemical Composition and Therapeutic Application. Evid Based Complement Alternat Med. 2015;2015:1-6. [cited by examiner]
European Office Action dated Mar. 11, 2024 for European Application No. 20739770.4. [cited by applicant]
Chinese Office Action dated Mar. 26, 2024 for Chinese Application No. 202080045740.0. [cited by applicant]
Chinese Search Report dated Mar. 26, 2024 for Chinese Application No. 202080045740.0. [cited by applicant]
Matziouridou, C., et al., “iNOS- and NOX1-dependent ROS production maintains bacterial homeostasis in the ileum of mice”, MucosalImmunology, Dec. 6, 2017, pp. 2-15. [cited by applicant]
Oh, C., et al., “Fermentation by Lactobacillus enhances anti-inflammatory effect of Oyaksungisan on LPS-stimulated RAW 264.7 mouse macrophage cells”, Complementary and Alternative Medicine, (2012), pp. 1-10, vol. 12, No… [cited by applicant]
Makarova K., et al., “Comparative genomics of the lactic acid bacteria”, PNAS, Oct. 17, 2006, pp. 15611-15616, vol. 103, No. 42. [cited by applicant]
Japanese Office Action dated Jan. 30, 2024 for Japanese Application No. 2021-576640. [cited by applicant]
Caliceti C., et al., “Comparative Study and Antioxidant and Immunomodulant activities between yeast and lab fermented papaya”, Functional Foods in Health and Disease, 2017, pp. 49-61, vol. 8, No. 1. [cited by applicant]
Barzegari, A., et al., “Effects of topical treatment of second-degree burn wounds with lactobacillus acidophilus on the wounds healing process in male rats”, Pharmaceutical and Biomedical Research, 2017, pp. 23-30, vol.… [cited by applicant]
Toumi et al., “Probiotic Bacterialactobacillus and Bifidobacterium Attenuate Inflammation in Dextran Sulfate Sodium-Induced Experimental Colitis in Mice” International Journal of Immunopathology and Pharmacology, vol. 2… [cited by applicant]
Labrie et al., “Complete Genome Sequence of [cited by applicant]
Makarova et al., “ [cited by applicant]
Lombardi et al., “Soluable fraction fro lysates of selected probiotic strains differently influences re-epitheliazation of HaCaT scratched monolayer through a mechanism involving nitric oxide synthase 2” Biomolecules, 2… [cited by applicant]